Rare illnesses are those that are hereditary, life-threatening, or chronically disabling that afflict fewer than 5 persons out of every 10,000. Because orphan illnesses are largely genetic in nature, the EMA is particularly interested in oncologic and metabolic orphan medications. To meet the EMA's orphan drug criteria, a medicine must be utilised for the diagnosis, prevention, or treatment of people suffering from a life-threatening or chronically debilitating illness. The total procedure for classification as an orphan drug (admission into the Community registry for orphan medical products) outlined in Art 5 ODR takes, in principle, six to eight months until the designation is granted. Following the completion of the designation procedure, the sponsor must seek for approval to place the product on the market. According to Regulation (EC) No 726/2004, this is accomplished through the centralised EC authorisation procedure. Currently, the organisation of centres of competence in Europe varies greatly: few nations have a designation mechanism in place, and the designation criteria differ from country to country, and sometimes even from region to region within a country. Rare illnesses were expressly addressed in the 2011 Directive 2011/24/EU on the implementation of patients' rights in cross-border healthcare. This Directive aims to improve access to health care for EU residents and stimulate collaboration among EU Member States in the field of health, with a special focus on rare illnesses, where patients and knowledge are few and dispersed across the EU. Despite these economic challenges, it is anticipated that the European experience would help other globe areas establish their own approaches to rare illness policy in order to better patient care

Orphan drugs, European council, European Union, Medical Agencies, Rare Diseases